Neurology: Results from a Phase 1 Study of Nusinersen (ISIS-SMNRX) in Children with Spinal Muscular Atrophy is organized by American Academy of Neurology (AAN) and will be held during Mar 08, 2016 - Mar 08, 2019.
The target audience for this medical event is physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits.
Learning Objectives :
Upon completion of the article by Chiriboga et al, the participant should be able to:
• List the most common adverse effects seen with nusinersen administration in this study
• State the CSF half-life of nusinersen seen in this study
• Discuss the effect of nusinersen administration on motor function in children with spinal muscular atrophy (SMA).
Additional details will be posted as soon as they are available.
Neurology, Clinical Genetics